Genetic Variation in <i>CYP2D6</i>, <i>UGT1A4</i>, <i>SLC6A2</i> and <i>SLCO1B1</i> Alters the Pharmacokinetics and Safety of Mirabegron

Mirabegron is a drug used in overactive bladder (OAB) treatment. Genetic variation in pharmacogenes might alter its pharmacokinetics, affecting its efficacy and safety. This research aimed to analyze the impact of genetic variation on mirabegron pharmacokinetics and safety. Volunteers from three bio...

Полное описание

Библиографические подробности

Главные авторы:	Paula Soria-Chacartegui, Patricia Cendoya-Ramiro, Eva González-Iglesias, Samuel Martín-Vílchez, Andrea Rodríguez-Lopez, Gina Mejía-Abril, Manuel Román, Sergio Luquero-Bueno, Dolores Ochoa, Francisco Abad-Santos
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2024-08-01
Серии:	Pharmaceutics
Предметы:	mirabegron pharmacogenetics <i>CYP2D6</i> overactive bladder pharmacokinetics
Online-ссылка:	https://www.mdpi.com/1999-4923/16/8/1077
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!